A Novel Sirolimus-Eluting Iron-Based Bioresorbable Scaffold Implantation in Single De Novo Coronary Lesions: Two-Year Clinical and Imaging Outcomes from the First in Man Study (IBS-FIM)

Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:

• Grant Support/Research Contract (Institutional) - Microport,Shanghai, China; LifeTech Scientific,Shenzhen, China